Reducing harmful oxidative stress in kidneys of people with chronic kidney disease by targeting FGF23
Controlling renal oxidative stress in CKD via targeting FGF23 bioactivity
The team will try to lower damaging oxidative stress in the kidneys of people with chronic kidney disease by targeting a blood hormone called FGF23.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Jackson Laboratory NIH-funded |
| Lab location | 1 site (Bar Harbor, United States) |
| Project ID | NIH-11135567 on NIH RePORTER |
What this research studies
Researchers are studying how the hormone FGF23 contributes to oxidative stress that harms kidney cells in chronic kidney disease. They will use genetic mouse models and single-cell chromatin profiling (scATAC‑seq) plus bioinformatics to find the key pathways that drive damage. The lab work will test whether blocking FGF23 activity or related oxidative pathways protects kidneys. The goal is to identify targets that could lead to new treatments to slow CKD progression and improve outcomes.
Who could benefit from this research
Good fit: People with chronic kidney disease who are interested in future clinical trials or in donating samples for research—especially those with signs of increased FGF23 or oxidative stress—would be the most relevant candidates.
Not a fit: People without chronic kidney disease or whose kidney problems are driven by causes unrelated to oxidative stress or FGF23 are unlikely to benefit directly from this work.
Why it matters
Potential benefit: If successful, this work could reveal new drug targets or therapies that slow kidney damage and delay progression of chronic kidney disease.
How similar studies have performed: Prior preclinical studies have linked FGF23 to oxidative stress and shown promise in models, but translating these findings into human treatments remains largely untested.
Where this research is happening
Bar Harbor, United States
- Jackson Laboratory — Bar Harbor, United States (Active)
Researchers
- Principal investigator: Agoro, Rafiou — Jackson Laboratory
- Study coordinator: Agoro, Rafiou
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.